

Completed acquisition by GLO Dutch Bidco B.V. of Mallinckrodt Netherlands Holdings B.V. and Mallinckrodt Nuclear Medicine LLC

Consent to certain actions for the purposes of the Initial Enforcement Order made by the Competition and Markets Authority (CMA) on 24 March 2017

We refer to your submission of 12 April 2017 requesting that the CMA consents to derogations to the Initial Enforcement Order of 24 March 2017 as amended on 12 April 2017 (the Order). The terms defined in the Order have the same meaning in this letter unless otherwise stated.

Under the Order, except with the prior written consent of the CMA, Mallinckrodt Medical B.V, IBA Molecular France SAS, CIS Bio International SAS and IBA Molecular UK Ltd shall not, during the specified period, take any action which might prejudice a reference of the transaction under section 22 of the Act or impede the taking of any remedial action following such reference.

After due consideration of your request for derogations from the Order, based on the information received from you and in the particular circumstances of this case, the following derogation in respect of the specific paragraph of the Order below is granted on the basis of two guiding principles:

- i) The UK business of Mallinckrodt will be ring-fenced and held separate during the period of the Initial Order and managed on a standalone basis by [X]; and
- ii) IBA Molecular¹ will maintain its supply of SPECT products through Alliance Medical during the period of the Initial Order, shall not amend or terminate the exclusive distribution agreement in place with Alliance Medical, shall maintain the same service levels under that agreement as prior to the

¹ IBA Molecular means the resultant businesses arising from the acquisition by GLO Dutch BidCo of Mallinckrodt Netherlands Holdings BV and Mallinckrodt Nuclear Medicine LLC excluding the former businesses of Mallinckrodt Netherlands Holdings BV and Mallinckrodt Nuclear Medicine LLC.

commencement date and shall operate this activity wholly independently of Mallinckrodt's activities in and/or related to the UK, including that it shall not share competitively sensitive information with Mallinckrodt's business with activities in and/or related to the UK.

Paragraph 5(l) of the Order

The following person, who following the carve out of Mallinckrodt from the seller's organisation, will provide back office customer service assistance to the Mallinckrodt UK business, will sign a Non-Disclosure Agreement in an agreed format to ensure that information which is specific to the UK business remains appropriately ring-fenced:

[✂]